China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS)
CNY 20.02
(-0.2%)
CNY 20.02
(-0.2%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 10.22 Billion | 9.44 Billion | 9.11 Billion | 8.5 Billion | 9.38 Billion | 8.22 Billion |
| Cost of Revenue | 4.6 Billion | 4.23 Billion | 4.02 Billion | 3.14 Billion | 3.43 Billion | 3.01 Billion |
| Gross Profit | 5.61 Billion | 5.21 Billion | 5.08 Billion | 5.35 Billion | 5.95 Billion | 5.21 Billion |
| Operating Expenses | 4.1 Billion | 3.9 Billion | 3.97 Billion | 4.12 Billion | 4.64 Billion | 4.03 Billion |
| Selling, General and Administrative Expenses | 3.24 Billion | 2.78 Billion | 2.95 Billion | 3.14 Billion | 3.85 Billion | 3.31 Billion |
| Research and Development Expenses | 561.45 Million | 474.71 Million | 409.59 Million | 291.01 Million | 202 Million | 144.74 Million |
| Other Expenses | 292.36 Million | 639.71 Million | 612.8 Million | 682.93 Million | 589.25 Million | -5.2 Million |
| Cost and Expenses | 8.7 Billion | 8.13 Billion | 8 Billion | 7.26 Billion | 8.07 Billion | 7.04 Billion |
| Operating Income | 1.51 Billion | 1.4 Billion | 1.13 Billion | 1.22 Billion | 1.26 Billion | 1.18 Billion |
| Interest Expense | 4.16 Million | 10.62 Million | 11.62 Million | 3.65 Million | 9.5 Million | 8.18 Million |
| Income Tax Expense | 240.61 Million | 199.25 Million | 149.05 Million | 201.52 Million | 195.34 Million | 194.65 Million |
| Earnings before Tax | 1.56 Billion | 1.41 Billion | 1.12 Billion | 1.21 Billion | 1.26 Billion | 1.18 Billion |
| Net Income | 1.33 Billion | 1.18 Billion | 935.68 Million | 1 Billion | 1.05 Billion | 968.59 Million |
| Earnings Per Share Basic | 1.30 | 1.14 | 0.90 | 0.96 | 1.01 | 0.93 |
| Earnings Per Share Diluted | 1.30 | 1.14 | 0.90 | 0.96 | 1.01 | 0.93 |
| Weighted Average Shares Outstanding | 1.02 Billion | 1.03 Billion | 1.04 Billion | 1.04 Billion | 1.04 Billion | 1.04 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.02 Billion | 1.03 Billion | 1.04 Billion | 1.04 Billion | 1.04 Billion | 1.04 Billion |
| Gross Margin | 0.55 | 0.55 | 0.56 | 0.63 | 0.63 | 0.63 |
| EBIT Margin | 0.22 | 0.21 | 0.18 | 0.20 | 0.18 | 0.19 |
| Profit Margin | 0.13 | 0.12 | 0.10 | 0.12 | 0.11 | 0.12 |
| EBITDA | 2.21 Billion | 1.99 Billion | 1.58 Billion | 1.59 Billion | 1.63 Billion | 1.54 Billion |
| Earnings Before Tax Margin | 0.15 | 0.15 | 0.12 | 0.14 | 0.13 | 0.14 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 2.61 Billion | 3.05 Billion | 2.8 Billion | 10.08 Billion | 2.67 Billion | 2.31 Billion |
| Cost of Revenue | 1.08 Billion | 1.3 Billion | 1.22 Billion | 4.94 Billion | 1.2 Billion | 1.07 Billion |
| Gross Profit | 1.52 Billion | 1.74 Billion | 1.57 Billion | 5.14 Billion | 1.47 Billion | 1.23 Billion |
| Operating Expenses | 1.13 Billion | 1.18 Billion | 1.11 Billion | 3.68 Billion | 1.19 Billion | 873.25 Million |
| Selling, General and Administrative Expenses | 1.75 Billion | 1.05 Billion | 991.57 Million | - | 364.63 Million | 1.07 Billion |
| Research and Development Expenses | 144.04 Million | 154.99 Million | 130.33 Million | - | 181.93 Million | 137.08 Million |
| Other Expenses | -763.77 Million | 30.4 Million | 3.46 Million | -14.53 Million | 35.47 Million | -5.37 Million |
| Cost and Expenses | 2.22 Billion | 2.49 Billion | 2.34 Billion | 8.63 Billion | 2.39 Billion | 1.94 Billion |
| Operating Income | 416.48 Million | 558.27 Million | 456.48 Million | 1.45 Billion | 241.25 Million | 367.35 Million |
| Interest Expense | 3.12 Million | 3.39 Million | 3.15 Million | 15.4 Million | 3.11 Million | 3.18 Million |
| Income Tax Expense | 61.18 Million | 38.69 Million | 105.7 Million | 240.61 Million | 23.92 Million | 74.04 Million |
| Earnings before Tax | 419.41 Million | 700.28 Million | 497.64 Million | 1.55 Billion | 276.72 Million | 361.97 Million |
| Net Income | 350.53 Million | 630.42 Million | 416.1 Million | 1.33 Billion | 255.25 Million | 300.97 Million |
| Earnings Per Share Basic | 0.34 | 0.61 | 0.40 | - | 0.25 | 0.29 |
| Earnings Per Share Diluted | 0.34 | 0.61 | 0.40 | - | 0.25 | 0.29 |
| Weighted Average Shares Outstanding | 1.02 Billion | 1.02 Billion | 1.03 Billion | 1.02 Billion | 1.02 Billion | 1.03 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.02 Billion | 1.02 Billion | 1.03 Billion | 1.02 Billion | 1.02 Billion | 1.03 Billion |
| Gross Margin | 0.58 | 0.57 | 0.56 | 0.51 | 0.55 | 0.53 |
| EBIT Margin | 0.16 | 0.24 | 0.19 | - | 0.13 | 0.16 |
| Profit Margin | 0.13 | 0.21 | 0.15 | 0.13 | 0.10 | 0.13 |
| EBITDA | 422.54 Million | 743.03 Million | 533.41 Million | - | 339.31 Million | 372.99 Million |
| Earnings Before Tax Margin | 0.16 | 0.18 | 0.16 | 0.14 | 0.09 | 0.16 |
NEXN
600114
POLY
300507
NPK
000970